Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.66 |
| ▸ | TLR2 | O60603 | 1/20 | 0.66 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.66 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18196579 | 0.88 | ERN1 (0.64) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL28228830 | 0.86 | ERN1 (0.62) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL5483924 | 0.83 | ERN1 (0.58) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL177279 | 0.81 | ALDH1A1 (0.55) | ERN1TLR2TLR1TLR6IRAK4 | |
| SCHEMBL2811830 | 0.80 | IRAK4 (0.48) | CA1CA2IRAK4CYP1A2MAPT | |
| SCHEMBL1748658 | 0.80 | SRC (0.45) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL16004 | 0.79 | ERN1 (1.00) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL929734 | 0.79 | ERN1 (1.00) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL30485148 | 0.79 | ERN1 (1.00) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL20764578 | 0.79 | TLR2 (0.45) | ERN1TLR2TLR1TLR6CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997627-B | Cyst amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-3672937-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| CN-110997627-A | Novel cystobacter amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019038405-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038405-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-28 | — | — | WO | disclosed |
| EP-2673257-B1 | PET/SPECT AGENTS FOR APPLICATIONS IN BIOMEDICAL IMAGING | UNIV WASHINGTON (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2673257-A2 | PET/SPECT AGENTS FOR APPLICATIONS IN BIOMEDICAL IMAGING | Washington University (US) | 2013-12-18 | — | — | EP | disclosed |
| CN-101258130-B | Isoquinolines as insulin-like growth factor-1 receptor inhibitors | ANALYTECON SA | 2012-11-28 | — | — | CN | disclosed |
| WO-2012109611-A2 | PET/SPECT AGENTS FOR APPLICATIONS IN BIOMEDICAL IMAGING | WASHINGTON UNIVERSITY (US) | 2012-08-16 | — | — | WO | disclosed |
| CN-100590118-C | Novel style heterocyclic compound as insulin-like growth factors first type acceptor inhibitor | ANALYTECON SA | 2010-02-17 | — | — | CN | disclosed |
| CN-101258130-A | Isoquinolines as insulin-like growth factor-1 receptor inhibitors | ANALYTECON SA (CH) | 2008-09-03 | — | — | CN | disclosed |
| CN-1922147-A | Novel style heterocyclic compound as insulin-like growth factors first type acceptor inhibitor | ANALYTECON SA (CH) | 2007-02-28 | — | — | CN | disclosed |
| EP-1135360-B1 | NOVEL 3-ALKOXYBENZYLAMINE DERIVATIVES AND THEIR USE AS MEDICINES FOR TREATING SCHIZOPHRENIA | PF MEDICAMENT (FR) | 2004-03-31 | — | — | EP | disclosed |
| US-6350913-B1 | AROMATIC AMINE COMPOUNDS | PIERRE FABRE MEDICAMENT (FR) | 2002-02-26 | — | — | US | disclosed |
| EP-1135360-A1 | NOVEL 3-ALKOXYBENZYLAMINE DERIVATIVES AND THEIR USE AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032557-A1 | NOVEL 3-ALKOXYBENZYLAMINE DERIVATIVES AND THEIR USE AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | ERN1 4555/4885TLR2 389/4885TLR1 663/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | ERN1 4532/4885TLR2 568/4885TLR1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.